Skip to main content
Premium Trial:

Request an Annual Quote

Eric Lander Joins Harvard Faculty, Keith Donne New CEO of Alantos, David Strack Becomes Genomic Solutions President, Michael Schubert VP R&D at Bruker Daltonics, and Others

Eric Landerhas joined the faculty of Harvard Medical School's systems biology department, the Harvard Crimson reported last week. He is the director of the Broad Institute and a professor at the Massachusetts Institute of Technology.


 

Keith Dionne has become chairman and CEO of Alantos Pharmaceuticals, the company said last week. He joins Alantos, based in Heidelberg, Germany, from Millennium Pharmaceuticals, where he was vice president of research and development strategy and vice president and general manager for technology business. Dionne holds a PhD in chemical engineering and an MS in technology policy from the Massachusetts Institute of Technology.

 

Alantos' acting CEO and CSO Fritz Frickel has become the company's executive vice president of research and development.


 

Gregory Libermanhas become general counsel and corporate secretary at CytRx, the company said on Monday. Previously, he worked as a strategic consultant and served as vice president for legal and corporate affairs and associate general counsel at Exodus Communications. Liberman holds a JD from the University of Chicago law school and a BA in economics from Stanford University.

 

Furthermore, Robert Brown has joined CytRx's scientific advisory board, the company said yesterday. He is a professor of neurology at Harvard Medical School and the founder and director of the Cecil B. Day Laboratory for Neuromuscular Research at Massachusetts General Hospital. Brown holds a medical degree from Harvard Medical School and a doctorate in neurophysiology from Oxford University in the UK.


 

David Strack has been promoted to president of Genomic Solutions, the parent company Harvard Bioscience said on Monday. He was previously vice president of sales and marketing at Genomic Solutions and will remain president of HBIO's subsidiary Union Biometrica.

 

Jeffrey Williams resigned as president of Genomic Solutions and as a member of the HBIO board to become CEO at another company.

 

In addition, Neal Harte has joined HBIO's board, replacing Christopher Dick, who resigned. Neal was previously executive vice president and vice chairman of Vitale, Caturano and Company.


 

Michael Schubert has been promoted to vice president for research and development at Bruker Daltonics, the parent company Bruker BioSciences said on Monday. Previously, he was responsible for Bruker Daltonics' R&D activities in Bremen, Germany, and served as managing director of Bruker Daltonik in Bremen and Leipzig. Schubert holds a doctorate in physics from the University of Hamburg in Germany.


 

Peter Johnson has become executive vice president and chief medical officer, and Mark Braughler vice president for business development in healthcare at Paradigm Genetics, following the company's acquisition of TissueInformatics, Paradigm said last week.

 

Johnson was chairman and CEO of TissueInformatics. He holds an MD from the State University of New York Upstate Medical Center and a BS from the University of Notre Dame.

 

Braughler was senior vice president for business development of TissueInformatics. He holds a PhD in pharmacology from the University of Pittsburgh School of Medicine.

 

In addition, Douglas Morton has joined Paradigm's board of directors, the company said yesterday. He is the CEO of the Southwest Michigan Innovation Center, and was a vice president at Pfizer until last year. Morton holds an AB in chemistry from Kenyon College and a PhD in organic chemistry from Columbia University.


 

Victor Markowitz has become chief informatics officer at the US Department of Energy Joint Genome Institute, the JGI said on Monday. Prior to joining JGI, he was chief information officer and senior vice president for data management systems at Gene Logic. Markowitz also heads the Biological Data Management and Technology Center within the Computational Research Division at Lawrence Berkeley National Laboratory. He holds DSc and MSc degrees in computer science from Technion, the Israel Institute of Technology.


 

Boyd Mulvey has joined the board of directors of NextGen Sciences, the company said last week. He is the CEO and founder of UK venture capital company Create Partners.


 

R. Janet Whitmore has joined the board of directors of Epoch Biosciences, the Bothell, Wash.-based company said last week. She is the founder and president of Benton Consulting. Whitmore holds a bachelor of science degree in chemical engineering from Purdue University and an MBA from Lewis University.

 

Also, Riccardo Pigliucci will not stand for re-election to Epoch's board in May, the company said. He is the chairman and CEO of Discovery Partners International in San Diego.


 

Wilfred van der Donk has joined the scientific advisory board of Divergence, the company said last month. He is an associate professor of chemistry at the University of Illinois at Urbana-Champaign.

 

Divergence, based in St. Louis, develops nematocidal chemicals.


 

Tony Pawson and Peter Singer have won Excellence in Health Research Awards from the Canadian Institutes of Health Research, the CIHR said yesterday.

 

Pawson is a proteomics researcher at the Samuel Lunenfeld Research Instituteat Mount Sinai Hospitalin Toronto, Canada.

 

Singer is a bioethicist at the University of Torontoand has been studying the impact of genomics in developed and developing countries.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.